ERBB2 and breast carcinoma: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer also showed that pCRs were higher in patients with HER2 IHC (+++) disease than HER2 IHC (++) (60.8% vs. 20.0%).